TGFBR1 and hepatocellular carcinoma: Galunisertib (LY2157299), a selective ATP-mimetic inhibitor ofTGFβRI/ALK5, is the only TGF-β pathway inhibitor currently under clinicalinvestigation in HCC patients (NCT01246986).